Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis

• Status: Terminated
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this trial was to compare the safety and efficacy of courses of tobramycin and ceftazidime, administered intravenously as either thrice daily short infusions or 24 h continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary PA infection. In conventional treatment regimens, ceftazidime is administered in the form of thrice daily short infusions, but pharmacodynamic considerations suggest that continuous infusion could be more effective.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
• Collaborators: Baxter Healthcare Corporation; GlaxoSmithKline; Roche Pharma AG; Vaincre la Mucoviscidose
• Treatments: Ceftazidime

Criteria

Inclusion Criteria:

• patients with cystic fibrosis older than 8 years

• with chronic Pseudomonas aeruginosa infection of the respiratory tract

• with at least 2 courses of IV antibiotic in the year before enrolment

• at the time of a pulmonary exacerbation

Exclusion Criteria:

• allergy to ceftazidime or tobramycin

• bronchial colonization with Burkholderia cepacia

• renal impairment

• history of lung transplantation